Background: Recent findings indicate that inhibitors of fatty acid amide hydrolase (FAAH) counteract the rewarding effects of nicotine in rats. Inhibition of FAAH increases levels of several endogenous substances in the brain, including the endocannabinoid anandamide and the noncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type peroxisome proliferator-activated nuclear receptors (PPAR-?). Here, we evaluated whether directly acting PPAR-? agonists can modulate reward-related effects of nicotine. Methods: We combined behavioral, neurochemical, and electrophysiological approaches to evaluate effects of the PPAR-? agonists [[4-Chloro-6-[(2,3-dimethylphenyl)amino]-2- pyrimidinyl]thio]acetic acid (WY14643) and methyl oleoylethanolamide (methOEA; a long-lasting form of OEA) on 1) nicotine self-administration in rats and squirrel monkeys; 2) reinstatement of nicotine-seeking behavior in rats and monkeys; 3) nicotine discrimination in rats; 4) nicotine-induced electrophysiological activity of ventral tegmental area dopamine neurons in anesthetized rats; and 5) nicotine-induced elevation of dopamine levels in the nucleus accumbens shell of freely moving rats. Results: The PPAR-? agonists dose-dependently decreased nicotine self-administration and nicotine-induced reinstatement in rats and monkeys but did not alter food- or cocaine-reinforced operant behavior or the interoceptive effects of nicotine. The PPAR-? agonists also dose-dependently decreased nicotine-induced excitation of dopamine neurons in the ventral tegmental area and nicotine-induced elevations of dopamine levels in the nucleus accumbens shell of rats. The ability of WY14643 and methOEA to counteract the behavioral, electrophysiological, and neurochemical effects of nicotine was reversed by the PPAR-? antagonist 1-[(4-Chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]- a,a-dimethyl-5-(1-methylethyl)-1H-Indole-2-propanoic acid (MK886). Conclusions: These findings indicate that PPAR-? might provide a valuable new target for antismoking medications.
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors
Pistis Marco;
2011
Abstract
Background: Recent findings indicate that inhibitors of fatty acid amide hydrolase (FAAH) counteract the rewarding effects of nicotine in rats. Inhibition of FAAH increases levels of several endogenous substances in the brain, including the endocannabinoid anandamide and the noncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type peroxisome proliferator-activated nuclear receptors (PPAR-?). Here, we evaluated whether directly acting PPAR-? agonists can modulate reward-related effects of nicotine. Methods: We combined behavioral, neurochemical, and electrophysiological approaches to evaluate effects of the PPAR-? agonists [[4-Chloro-6-[(2,3-dimethylphenyl)amino]-2- pyrimidinyl]thio]acetic acid (WY14643) and methyl oleoylethanolamide (methOEA; a long-lasting form of OEA) on 1) nicotine self-administration in rats and squirrel monkeys; 2) reinstatement of nicotine-seeking behavior in rats and monkeys; 3) nicotine discrimination in rats; 4) nicotine-induced electrophysiological activity of ventral tegmental area dopamine neurons in anesthetized rats; and 5) nicotine-induced elevation of dopamine levels in the nucleus accumbens shell of freely moving rats. Results: The PPAR-? agonists dose-dependently decreased nicotine self-administration and nicotine-induced reinstatement in rats and monkeys but did not alter food- or cocaine-reinforced operant behavior or the interoceptive effects of nicotine. The PPAR-? agonists also dose-dependently decreased nicotine-induced excitation of dopamine neurons in the ventral tegmental area and nicotine-induced elevations of dopamine levels in the nucleus accumbens shell of rats. The ability of WY14643 and methOEA to counteract the behavioral, electrophysiological, and neurochemical effects of nicotine was reversed by the PPAR-? antagonist 1-[(4-Chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]- a,a-dimethyl-5-(1-methylethyl)-1H-Indole-2-propanoic acid (MK886). Conclusions: These findings indicate that PPAR-? might provide a valuable new target for antismoking medications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
